Liver iron overload is defined as an accumulation of the chemical element Fe in the hepatic parenchyma that exceeds the normal storage. When iron accumulates, it can be toxic for the liver by producing inflammation and cell damage. This can potentially lead to cirrhosis and hepatocellular carcinoma, as well as to other liver lesions depending on the underlying condition associated to liver iron overload. The correct assessment of liver iron storage is pivotal to drive the best treatment and prevent complication. Nowadays, magnetic resonance imaging (MRI) is the best non-invasive modality to detect and quantify liver iron overload. However, due to its superparamagnetic properties, iron provides a natural source of contrast enhancement that can make challenging the differential diagnosis between different focal liver lesions (FLLs). To date, a fully comprehensive description of MRI features of liver lesions commonly found in iron-overloaded liver is lacking in the literature. Through an extensive review of the published literature, we aim to summarize the MRI signal intensity and enhancement pattern of the most common FLLs that can occur in liver iron overload.
Background: Patients with repaired Tetralogy of Fallot (rTOF) often develop pulmonary regurgitation (PR) and right ventricle (RV) dysfunction, experiencing increased mortality and morbidity rates in adulthood. Pulmonary valve replacement (PVR) timing to address PR is controversial. Cardiac Magnetic Resonance (CMR) is the gold standard for morpho-functional evaluation of complex cardiopathies. This study aims to identify CMR parameters predictive of adverse outcomes to help defining the best therapeutic management of rTOF patients. Methods: 130 rTOF patients who underwent CMR (2006–2019) were enrolled in this retrospective single-center study. CMR, clinical, ECG and exercise data were analyzed. Univariate and multivariate analyses identified clinical and CMR parameters predictive of adverse outcomes both individually (e.g., death, arrhythmias, heart failure (HF), pharmacological therapy, QRS ≥ 160ms) and as composite outcome. Results: Univariate analysis confirmed RV volumes and RV ejection fraction corrected for PR as adverse outcome predictors and identified interesting correlations: pulmonary artery bifurcation geometry and abnormal interventricular septum (IVS) motion with arrhythmias (p < .001; p = .037), HF (p = .049; p = .005), composite outcome (p = .039; p = .009); right atrium (RA) dimensions with the composite outcome and the outcomes individually (p < .001). The best predictive models by multivariate analysis included sex (male), RV and RA dilation for QRS ≥ 160ms, time form repair to CMR, age at TOF repair and IVS fibrosis for pharmacological therapy. Conclusions: Besides RV volumes, new adverse prognostic factors could guide rTOF therapeutic management: pulmonary arteries morphology, abnormal IVS motion, RV dysfunction, RA dilation. Perspective multicentric evaluation is needed to specify their effective role.
In the literature, it has repeatedly been stated that the introduction of hepatospecific contrast agents in Magnetic Resonance Imaging prolongs the acquisition time due to the hepatobiliary phase, normally acquired 15–20 min after injection. Many efforts have been made to shorten the time-consuming protocols, and it was demonstrated that T2-Weighted Images (T2WI) and Diffusion-Weighted Images (DWI) acquired after Gd-EOB-DTPA show a comparable diagnostic capability to pre-contrast T2WI and DWI in the detection and characterization of hepatic tumors. Therefore, T2WI and DWI are usually acquired after the acquisition of vascular phases, in the dead time until the acquisition of the hepatobiliary phase. Unfortunately, contrast agents, especially Gd-EOB-DTPA, reduce the hydrogen nuclei’s relaxation time and modify signal intensity. We report a case in which, due to these limitations of the acquisition protocol, two hemangiomas showed an inhomogeneous, low signal on T2WI and DWI that was not visible in a follow-up scan a few days later. In conclusion, when liver lesions of unknown nature must be characterized, and there is a lack of previous radiological investigations, it could be useful to acquire pre-contrast T2WI and DWI to avoid diagnostic confusion, especially in non-tertiary centers.
4 June 2024 in Journal of Medical Imaging and Interventional Radiology
Purpose: To retrospectively evaluate the safety and efficacy of computed tomography (CT)-guided drainage of presacral fluid collections. Methods: The records of patients who underwent percutaneous CT-guided drainages of presacral fluid collections at our institution from January 2015 to October 2023 were retrospectively reviewed. Demographics and morphological data, procedural details, complications, and outcomes were analyzed. Results: In all, 93 patients with 95 presacral fluid collections received percutaneous CT-guided drainages. A total of 117 procedures were performed with 18 patients who required re-drainages. Technical and radiological success rate of drainage placement procedures was, respectively, 98% and 78%. One of 93 [1%] patients experienced a minor complication from drainage placement. No major complications occurred. The preferred approach was left infrapiriformis transgluteal in prone position. Median drainage size was 10 Fr (range 6–14 Fr). Conclusions: Percutaneous CT-guided drainage is a safe and effective treatment option for presacral fluid collections, which in selected cases can be used as an alternative to surgery or as a preparatory phase for it, with minor complications occurring rarely.
Purpose Evaluate Late Iodine Enhancement (LIE) using the new Philips Spectral CT 7500 scanner without ECG-gating. Material and Methods Fifty-one contrast-enhanced cardiac Computed Tomography (CT) scans with LIE phase (LIE-CT) acquired using the Philips Spectral CT 7500 scanner (8 cm, 256 reconstructed slices) were retrospectively reviewed. LIE-CT was acquired 6–7 min after the administration of contrast agent, using ultra-short scanning time without ECG-gating. LIE-CT technical and dosimetry data were compared with data from 17 cardiac CT scans acquired with Philips Brilliance iCT (4 cm, 128 reconstructed slices). On Spectral CT images, LIE was assessed using "Iodine no water" spectral maps and Extracellular Volume (ECV) quantification. CT findings were compared with the gold standard (Cardiac Magnetic Resonance, CMR) when available. Results Spectral CT images without ECG-gating exhibited high visual quality with minimal motion artifacts. Technical data significantly differed (p < .001) between Spectral CT and iCT: median scan time 0.69 s (interquartile range (IQR) 0.66–0.72) vs 8.02 s (IQR 7.32–8.49), median Table speed 433.2 mm/s vs 23.5 mm/s (IQR 21.8–26.5), median CTDIvol 7.2 mGy vs 29.6 mGy (IQR 27.8–33.3), median DLP 211 mGy*cm (IQR 199–222) vs 477.6 mGy*cm (IQR 430.9–551.7), current 812 mA vs 924 mA (IQR 924–925), voltage 100 kV (min 100–max 140) vs 80 kV. Interobserver reproducibility of ECV quantification on Spectral CT images was good in myocardium without LIE and excellent in LIE areas, with negligible bias between observers. Where available, LIE and ECV findings showed good concordance with CMR LGE and ECV. Conclusion Ultrafast non-ECG-gated cardiac Spectral CT provides high-quality images for evaluating LIE, 76% reduction of radiation dose, 50% increase in signal-to-noise ratio, and 91% reduction of acquisition time. ECV measurements demonstrate high interobserver reproducibility. Preliminary findings show good agreement with CMR; while based on a limited validation cohort with selective ECV use.
A man in his 40s presented to our Hospital with abdominal pain, jaundice, and pruritus. He had a history of Alagille Syndrome treated with cholecystojejunostomy in the neonatal period because of initial misdiagnosis of biliary atresia. Laboratory investigations showed hyperbilirubinemia (total bilirubin 1.76 mg/dL [<1.2 mg/dL]; conjugated 1.06 mg/dL [<0.3 mg/dL]) and cholestasis (GGT 78 U/L [<50 U/L]; ALP 200 U/L [<50 U/L]). Transabdominal ultrasound was limited by aerobilia due to the cholecystojejuno-anastomosis. Subsequent basal CT scan revealed an impacted stone within the patient's native common bile duct (CBD). Aerobilia in intrahepatic bile ducts and gallbladder was reported. Magnetic Resonance cholangiopancreatography confirmed the gallstone in the CBD compressing cystic duct and common hepatic duct, with dilation of the upstream bile ducts. Furthermore, the native CBD was obstructed by other gallstones. In Mirizzi syndrome, gallstones impacted in gallbladder's Hartmann's pouch or cystic duct extrinsically compress CBD. We suggest naming the present condition “Reverse Mirizzi Syndrome” (Renzulli Matteo Syndrome, RMS) because it is the exact opposite of Mirizzi syndrome.